One of Northern Ireland’s leading scientists has received a top UK award, to support ground-breaking research into vascular stem cells and eye disease at Queen’s University.
Fera Pharmaceuticals Launches OTC Puralube(R) Ophthalmic Ointment For Dry Eye
Puralube® Ophthalmic Ointment, is now available from Fera Pharmaceuticals. Puralube, a preservative free ophthalmic ointment, is one that has been relied upon by patients and healthcare professionals for years to relieve the symptoms of dry eye. When…
ACUMINDER™ Tool Helping To Change Contact Lens Wearing Behavior, Survey Shows
Even though eye care doctors and manufacturers provide instructions about caring for and wearing contact lenses, studies show that many contact lens wearers do not comply with the recommended replacement frequencies and fail to discard their lenses aft…
UM researchers find genetic cause of retinitis pigmentosa
Researchers led by geneticists at the University of Miami Miller School of Medicine have identified a new gene that causes retinitis pigmentosa, a form of blindness, ending one South Florida family’s nearly 20-year search for what caused three of their…
Alimera reports 36-month results from ILUVIEN Phase 3 FAME study for DME
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported results through month 36 of the completed FAME™ Study.
Positive top-line results from ILUVIEN Phase 3 trial in patients with DME
pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN for the treatment of Diabetic Macular Edema, today announced month 36, top-line readou…